Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hepatocellular Cancer
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Percentage patients consenting for assessment out of number of patients approached
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
Detailed Description
This study is primarily looking to see if it is feasible to assess frailty in patients with advanced hepatocellular cancer. It is also evaluating whether there may be any correlation between these assessments and toxicity of treatment and outcome. The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed measuring muscle mass from imaging performed as part of routine clinical care. The assessments will be performed at baseline on entry into the study, at week 9 and week 18. There is the option for patients to also donate a blood samples for research purposes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a diagnosis of hepatocellular cancer not suitable for curative treatment
- •Seen by an oncologist or hepatologist for consideration of palliative treatment and a decision regarding management already made
- •WHO Performance status 0-2
- •Childs Pugh Score A or B
- •Written informed consent
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Percentage patients consenting for assessment out of number of patients approached
Time Frame: baseline
Number of patients consenting for the study as a percentage of the number of patients approached about the study
Time taken to complete assessments
Time Frame: Baseline, week 9 and week 18
Time taken to completed assessments recorded by clinical trials officer
Secondary Outcomes
- Frailty as a predictor of grade 3/4 toxicity(Baseline, week 9 and week 18)
- Muscle mass and timed get up and go as predictors of outcome(Baseline, week 9 and week 18)